J Korean Soc Endocrinol.  2005 Dec;20(6):608-615. 10.3803/jkes.2005.20.6.608.

Osteoporosis and Atherosclerosis: Current and New Potential Medicines Targeting Both Diseases

• Lim SK
• Park SY

• KMID: 1572443
• DOI: http://doi.org/10.3803/jkes.2005.20.6.608

Abstract

No Abstract available.

MeSH Terms

Atherosclerosis*
Osteoporosis*

Figure

• 

  Fig. 1. Mevalonic acid pathway and action sites of statins and bisphosphonates.

• 

  Fig. 2. The involvements of PTH, PTHrP, and their shared PTHR1 receptor in vascular ossification.

Reference

References

1. Whitney C, Warburton D, Frohlich J, Chan S, McKay H, Khan K. Are cardiovascular disease and osteoporosis directly linked? Sports Med. 2004; 34:779–807.

2. Mundy G, Garrett R, Harris S, Chan J, Chen D, Rossini G, Boyce B, Zhao M, Gutierrez G. Stimulation of bone formation in vitro and in rodents by statins. Science. 1999; 286:1946–1949.

3. Maritz F, Conradie M, Hulley P, Gopal R, Hough S. Effect of statins on bone mineral density and bone histomorphometry in rodents. Arteriosclrer Thromb Vasc Biol. 2001; 21:1636–1641.

4. Meier C, Schlienger R, Kraenzlin M, Schlegel B, Jick H. HMG-CoA reductase inhibitors and the risk of fractures. JAMA. 2000; 283:3205–3210.

5. Mundy G. Statins and their potential for osteoporosis. Bone. 2001; 29:495–497.

6. Watanabe S, Fukumoto S, Takeuchi Y, Fujita H, Nakano T, Fujita T. Effects of 1-year treatment with fluvastatin or pravastatin on bone. Am J Med. 2001. 110:p. 584–587.

7. LaCroix A, Cauley J, Pettinger M, Hsia J, Bauer D, McGowan J, Chen Z, Lewis C, McNeeley G, Passaro M, Jackson R. Statin Use, Clinical Fracture, and Bone Density in Postmenopausal Women: Results from the Women’s Health Initiative Observational Study. Ann Intern Med. 2003; 139:97–104.

8. Adami S, Braga V, Guidi G, Gatti D, Gerardi D, Fracassi E. Chronic intravenous aminobisphosphonate therapy increases high-density lipoprotein cholesterol and decreases low-density lipoprotein cholesterol. J Bone Miner Res. 2000; 15:599–604.

9. Rogers M, Gordon S, Benford H, Coxon F, Luckman S, Monkkonen J, Frith J. Cellular and Molecular Mechanisms of Action of Bisphosphonates. Cancer 15;. 2000; 88:2961–2978.

10. Ylitalo R. Bisphosphonates and atherosclerosis. Gen Pharm. 2002; 35:287–296.

11. Kramsch D, Aspen A, Rozler L. Atherosclerosis: prevention by agents not affecting abnormal levels of blood lipids. Science. 1981; 213:1511–1512.

12. Koshiyama H, Nakamura Y, Tanaka S, Minamikawa J. Decrease in carotid intima-media thickness after 1-year therapy with Etidronate for osteopenia associated with type 2 diabetes. J Clin Endocrinol Metab. 2005; 85:2793–2796.

13. L Tankó, G Qin, P Alexandersen, Y Bagger, C Christiansen. Effective doses of ibandronate do not influence the 3-year progression of aortic calcification in elderly osteoporotic women. Osteoporos Int. 2005; 16:184–190.

14. Shimshi M, Abe E, Fisher E, Zaidi M, Fallon J. Bisphosphonates induce inflammation and rupture of atherosclerotic plaques in apolipoprotein-E null mice. Biochem Biophys Res Commun. 2005; 328:790–793.

15. Barrett-Connor E, Cox D, Anderson P. The potential of SERMs for reducing the risk of coronary heart disease. Trends Endocrinol Metab. 1999; 10:320–325.

16. Williams J, Wagner J, Li Z, Golden D, Adams M. Tamoxifen inhibits arterial accumulation of LDL degradation products and progression of coronary artery atherosclerosis in monkeys. Arterioscler Thromb Vasc Biol. 1997; 17:403–408.

17. Ke H, Chen H, Simmons H, Qi H, Crawford D, Pirie C, Chidsey-Frink K, Ma Y, Jee W, Thompson D. Comparative effects of droloxifene, tamoxifen, and estrogen on bone, serum cholesterol, and uterine histology in the ovariectomized rat model. Bone. 1997; 20:31–39.

18. Figtree G, Lu Y, Webb C, Collins P. Raloxifene Acutely Relaxes Rabbit Coronary Arteries In Vitro by an Estrogen Receptor–Dependent and Nitric Oxide–Dependent Mechanism. Circulation. 1999; 100:1095–1101.

19. Zuckerman S, Bryan N. Inhibition of LDL oxidation and myeloperoxidase dependent tyrosyl radical formation by the selective estrogen receptor modulator raloxifene. Atherosclerosis. 1996; 126:65–75.

20. Walsh B, Kuller L, Wild R, Paul S, Farmer M, Lawrence J, Shah A, Anderson P. Effects of Raloxifene on Serum Lipids and Coagulation Factors in Healthy Postmenopausal Women. JAMA. 1998; 279:1445–1451.

21. Stamatelopoulos K, Lekakis J, Poulakaki N, Papamichael C, Venetsanou K, Aznaouridis K, Protogerou A, Papaioannou T, Kumar S, Stamatelopoulos S. Tamoxifen improves endothelial function and reduces carotid intima-media thickness in postmenopausal women. Am Heart J. 2004; 147:1093–1099.

22. Early Breast Cancer Trialists’ Collaborative Group . Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998; 351:1451–1467.

23. Mosca L, Barrett-Connor E, Wegner N, Collins P, Grady D, Kornitzer M, Moscarelli E, Paul S, Wright T, Helterbrand J, Anderson P. Design and methods of the Raloxifene Use for the Heart (RUTH) study. Am J Cardiol. 2001; 88:392–395.

24. Hamerman D. Osteoporosis and atherosclerosis: biological linkages and the emergence of dual-purpose therapies. Q J Med. 2005; 98:467–484.

25. Kontogianni M, Dafni U, Routsias J, Skopouli F. Blood leptin and adiponectin as possible mediators of the relation between fat mass and BMD in perimenopausal women. J Bone Miner Res. 2004; 19:546–551.

26. Akune T, Ohba S, Kamekura S, Yamaguchi M, Chung U, Kubota N, Terauchi Y, Harada Y, Azuma Y, Nakamura K, Kadowaki T, Kawaguchi H. PPARgamma insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J Clin Invest. 2004; 113:846–855.

27. Ali A, Weinstein R, Stewart S, Parfitt A, Manolagas S, Jilka R. Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology. 2005; 146:1226–1235.

28. Whitfield J. Osteogenic PTHs and vascular ossification-Is there a danger for osteoporotics? J Cell Biochem. 2005; 95:437–444.

29. Martin-Ventura JL, Ortego M, Esbrit P, Hernandez-Presa MA, Ortega L, Egido J. Possible role of parathyroid hormone-related protein as a proinflmammatory cytokine in atherosclerosis. Stroke. 2003; 34:1783–1789.

30. Shao J, Cheng S, Charlton-Kachigian N, Loewy A, Towler D. Teriparatide (Human Parathyroid Hormone (1-34)) inhibits osteogenic vascular calcification in diabetic low density lipoprotein receptor-deficient mice. J Biol Chem. 2003; 278:50195–50202.

31. Sattler A, Schoppet M, Schaefer J, Hofbauer L. Novel aspects on RANKL ligand and osteoprotegerin in osteoporosis and vascular disease. Calcif Tissue Int. 2004; 74:103–106.

32. Price P, June H, Buckley J, Williamson M. Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. Arterioscler Thromb Vasc Biol. 2001; 21:1610–1616.

33. Browner W, Lui L, Cummings S. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab. 2001; 86:631–637.

34. Schoppet M, Schaefer J, Hofbauer L. Low serum levels of soluble RANK ligand are associated with the presence of coronary artery disease in men. Circulation. 2003; :76.

35. Schoppet M, Preissner K, Hofbauer L. RANK ligand and osteoprotegerin paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb Vasc Biol. 2002; 22:549–553.

36. Bekker P, Holloway D, Nakanishi A, Arrighi M, Leese P, Dunstan C. The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone MinerRes. 2001; 16:348–360.

37. Klein R, Allard J, Avnur Z, Nikolcheva T, Rotstein D, Carlos A, Shea M, Waters R, Belknap J, Peltz G, Orwoll E. Regulation of bone mass in mice by the lipoxygenase gene Alox15. Science. 2004; 303:229–232.

38. Cornicelli J, Trivedi B. 15-Lipoxygenase and its inhibition: a novel therapeutic target for vascular disease. Curr Pharm Des. 1999; 5:11–20.

39. Magoori K, Kang M, Ito M, Kakuuchi H, Ioka R, Kamataki A, Kim D, Asaba H, Iwasaki S, Takei Y, Sasaki M, Usui S, Okazaki M, Takahashi S, Ono M, Nose M, Sakai J, Fujino T, Yamamoto T. Severe hypercholesterolemia, impaired fat tolerance, and advanced atherosclerosis in mice lacking both low density lipoprotein receptor-related protein 5 and apolipoprotein E. J Biol Chem. 2003; 278:11331–11336.